The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $170.17

Today's change+1.69 +1.00%
Updated December 19 4:15 PM EST. Delayed by at least 15 minutes.
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $170.17

Today's change+1.69 +1.00%
Updated December 19 4:15 PM EST. Delayed by at least 15 minutes.

Amgen Inc up (U.S.)$1.69

Amgen Inc closed up Friday by (U.S.)$1.69 or 1.00% to (U.S.)$170.17. Over the last five days, shares have gained 3.43% and are currently 1.72% off of the 52-week high. Shares have outperformed the S&P 500 by 36.70% during the last year.

Key company metrics

  • Open(U.S.) $168.91
  • Previous close(U.S.) $168.48
  • High(U.S.) $171.73
  • Low(U.S.) $167.40
  • Bid / Ask-- / --
  • YTD % change+49.17%
  • Volume7,856,281
  • Average volume (10-day)4,141,465
  • Average volume (1-month)3,387,244
  • Average volume (3-month)4,087,006
  • 52-week range(U.S.) $108.20 to (U.S.) $173.14
  • Beta0.51
  • Trailing P/E26.78×
  • P/E 1 year forward19.76×
  • Forward PEG1.77×
  • Indicated annual dividend(U.S.) $3.16
  • Dividend yield1.86%
  • Trailing EPS(U.S.) $6.35
Updated December 19 4:15 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.74%

Based on its net profit margin of 24.74%, Amgen Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,0315,1804,5215,011
Total other revenue--------
Total revenue5,0315,1804,5215,011
Gross profit4,1624,3023,4313,982
Total cost of revenue8698781,0901,029
Total operating expense3,5653,2783,1573,824
Selling / general / administrative1,2131,1361,0231,306
Research & development1,0181,0181,0271,249
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)529226--215
Other operating expenses, total-64201725
Operating income1,4661,9021,3641,187
Interest income (expense), net non-operating-269-282-259-261
Gain (loss) on sale of assets--------
Other--------
Income before tax1,3371,7581,2041,014
Income after tax1,2441,5471,0731,021
Income tax, total93211131-7
Net income1,2441,5471,0731,021
Total adjustments to net income--------
Net income before extra. items1,2441,5471,0731,021
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,2441,5471,0731,021
Inc. avail. to common incl. extra. items1,2441,5471,0731,021
Diluted net income1,2441,5471,0731,021
Dilution adjustment0------
Diluted weighted average shares771768768768
Diluted EPS excluding extraordinary itemsvalue per share1.612.011.401.33
Dividends per sharevalue per share0.610.610.610.47
Diluted normalized EPSvalue per share2.252.271.401.51